September 26, 2024 09:00 PM EDT
R&D
Special

End­points 11 win­ner Xaira Ther­a­peu­tics: Biotech’s largest AI bet with A-list back­ers

Andrew Dunn

Senior Biopharma Correspondent

↑
  • CEO Marc Tessier-Lav­i­gne
  • To­tal raised More than $1 bil­lion in com­mit­ted cap­i­tal
  • Head­quar­ters South San Fran­cis­co, CA

David Bak­er’s Seat­tle …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

Steve Davis leaves Aca­dia, re­placed by Bris­tol My­ers alum; For­mer J&J ex­ec to lead R&D at No­vavax

Cas­sa­va and its for­mer ex­ecs set­tle SEC charges for ‘mis­lead­ing’ Alzheimer’s drug da­ta

Tra­vere halts Phase 3 in­her­it­ed dis­ease tri­al due to man­u­fac­tur­ing scale-up is­sue

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times